ZOHé: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid Malignancies  Gandhi Laurent Damaj, Omar Benbrahim, Maya Hacini, Inna Voronina, Khaled Benabed, Ravaka-Fatoma Soumoudronga, Isabelle Gasnereau, Corinne Haioun, Philippe Solal-Céligny  Clinical Lymphoma, Myeloma and Leukemia  Volume 17, Issue 6, Pages 362-369.e2 (June 2017) DOI: 10.1016/j.clml.2017.05.002 Copyright © 2017 The Authors Terms and Conditions

Figure 1 Description of Severe Neutropenia Episodes During Study Follow-Up, by Subgroup (n = 175) Abbreviations: HL = Hodgkin lymphoma; HM = hematological malignancies; NHL = non-Hodgkin lymphoma. Clinical Lymphoma, Myeloma and Leukemia 2017 17, 362-369.e2DOI: (10.1016/j.clml.2017.05.002) Copyright © 2017 The Authors Terms and Conditions

Supplemental Figure 1 Study Population for the HM Cohort. ∗Four Patients Were Excluded From the Analysis: 2 Due to Deviation From the Eligibility Criteria and 2 Were Duplicated Patient Records. †The 18 Patients Who Left the Study Prematurely and Were Not Followed Up Were Comparable to the Followed-Up Patients in Terms of Age, Sex, Comorbidities Concomitant With Neutropenia Risk, and Number of Chemotherapy Cycles Planned. There Were More Patients With Prior Episodes of Neutropenia (P = .04) and Patients Had a Lower Performance Score (P < .01) at Inclusion Compared With the Followed-Up Patients. ‡Sixty-Three of These Patients Left the Study Before the 3-Month Follow-Up Visit but Were Reviewed for Data Collection Abbreviation: HM = hematological malignancies. Clinical Lymphoma, Myeloma and Leukemia 2017 17, 362-369.e2DOI: (10.1016/j.clml.2017.05.002) Copyright © 2017 The Authors Terms and Conditions